Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05774717 · ClinicalTrials.gov registry record · Phase 1
Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis
A Phase 1 study of Surgery and Postoperative Blood Loss, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05774717: Recruiting Phase 1 study of Surgery and Postoperative Blood Loss, sponsored by Vanderbilt University Medical Center.
NCT05774717 is a Phase 1 study of Surgery and Postoperative Blood Loss that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 60 participants, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05774717, a Phase 1 study of Surgery and Postoperative Blood Loss, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a prospective randomized study to evaluate the effect of tranexamic acid (TXA) use on intraoperative and postoperative outcomes among patients undergoing rhinoplasty by two Facial Plastic surgeons at Vanderbilt. Outcomes will include intra- and post-operative bleeding and postoperative bruising and swelling.
Primary Outcome
Weight of surgical sponges used (grams)
Conditions Studied
Interventions
- DRUG Tranexamic acid
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2026-02-01 |
| Phase | Phase 1 |
What NCT05774717 shows while recruiting
NCT05774717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Surgery appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic acid is the first listed.
NCT05774717 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05774717 about?
NCT05774717 is a clinical study titled "Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis". This study will be a prospective randomized study to evaluate the effect of tranexamic acid (TXA) use on intraoperative and postoperative outcomes among patients undergoing rhinoplasty by two Facial Plastic surgeons at Vanderbilt. Outcomes will include intra- and post-operative bleeding and postoper...
What is the current status of trial NCT05774717?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-04-01. Estimated completion is 2026-02-01.
What conditions does trial NCT05774717 study?
This clinical trial studies the following conditions: Surgery, Postoperative Blood Loss.
What interventions are being tested in trial NCT05774717?
The interventions under investigation include: Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT05774717?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05774717 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05774717's enrollment target sits among peer trials
60 81st of 120 higher than 36 of 120 other Surgery trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgery trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
COMPLETED · Phase 1
-
Terumo Aortic Global Endovascular Registry
RECRUITING
-
A Study of the Use of 3D Technology to Guide Head and Neck Surgery
RECRUITING · NA
-
Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial
RECRUITING · Phase 4
-
NO During CPB in Neonates to Reduce Risk of AKI
RECRUITING · Phase 3
-
INCLUDE Program: A Perioperative Wellness Program Tailored for Black Surgical Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI